<p>Tivic Health Systems, Inc. ((TIVC)) 已召開其第三季度財報電話會議。請繼續閲讀會議的主要亮點。</p>
<h3>認識您的 ETF AI 分析師</h3>
<ul>
<li>瞭解 TipRanks 的 <em>ETF</em> AI 分析師如何幫助您做出更明智的投資決策</li>
<li>探索 TipRanks 用户喜愛的 ETF，並查看 <strong><em>ETF</em> AI 分析師</strong> 對您關注的 ETF 的見解。</li>
</ul>
<p>儘管面臨淨虧損增加和生產延遲等挑戰，Tivic Health Systems, Inc. 在其戰略轉型和 Entolimod 的開發方面取得了顯著進展。財報電話會議期間的整體情緒樂觀，突顯了公司的進步和改善的財務狀況。</p>
<h2>戰略轉型</h2>
<p>Tivic Health 成功地將其重點從生物電子學擴展到生物製藥，特別是針對與免疫系統相關的治療。這一戰略轉變標誌着公司的一次重大轉型，使其在生物製藥這一前景廣闊的領域中佔據了有利位置。</p>
<h2>Entolimod 開發進展</h2>
<p>公司在 Entolimod 的開發方面取得了進展，轉移了兩個新藥研究申請 (INDs) 並完成了細胞系驗證。這些步驟對於 Tivic 在將 Entolimod 作為軍事對策和儲備藥物的製造準備方面至關重要。</p>
<h2>財務狀況</h2>
<p>Tivic Health 的財務狀況得到加強，現金及現金等價物從 200 萬美元上升至 350 萬美元，公司保持無債務的資產負債表。這一改善為未來的增長提供了堅實的基礎。</p>
<h2>毛利率改善</h2>
<p>公司報告稱毛利率有所改善，排除庫存準備金後，毛利率從去年的 35% 增加至 42%。這表明成本管理和運營效率有所提升。</p>
<h2>淨虧損增加</h2>
<p>儘管有積極的發展，Tivic Health 在 2025 年第三季度的淨虧損增加至 260 萬美元，而 2024 年第三季度為 140 萬美元。這一淨虧損的增加反映了公司在其戰略轉型中的持續投資。</p>
<h2>生產延遲</h2>
<p>由於合同製造商面臨的財務壓力，Tivic 的生產計劃遭遇延遲。這些延遲對公司的生產時間表構成挑戰。</p>
<h2>銷售成本增加</h2>
<p>銷售成本顯著上升至 291,000 美元，較 82,000 美元大幅增加，主要由於庫存準備金。這一增加影響了公司的整體盈利能力。</p>
<h2>九個月收入下降</h2>
<p>九個月期間的收入從 2024 年的 600,000 美元下降至 302,000 美元，歸因於單位銷售減少。這一下降突顯了在維持銷售勢頭方面面臨的挑戰。</p>
<h2>前瞻性指導</h2>
<p>展望未來，Tivic Health 致力於向生物製藥市場的戰略轉型，重點關注 Entolimod 作為急性輻射綜合症 (ARS) 的軍事對策。公司在與 ARS 和晚期癌症相關的 IND 轉移方面取得了進展。儘管九個月收入有所下降，Tivic 對未來持樂觀態度，得益於毛利率的改善和現金儲備的增加。</p>
<p>總之，Tivic Health Systems, Inc. 正在經歷一個轉型階段，專注於生物製藥和 Entolimod 的開發。儘管公司面臨淨虧損增加和生產延遲等挑戰，但其改善的財務狀況和戰略重點為未來提供了良好的前景。</p>

TIVC

<p>Tivic Health Systems, Inc. 舉行了第三季度財報電話會議，強調其從生物電子學向生物製藥的戰略轉變，專注於免疫系統治療。儘管面臨淨虧損增加和製造延遲等挑戰，公司改善了財務狀況，現金儲備上升至 350 萬美元，資產負債表無債務。毛利率提高至 42%，儘管淨虧損增加至 260 萬美元。Tivic 對未來持樂觀態度，專注於 Entolimod 的開發作為軍事對策，儘管九個月的收入有所下降</p>

<p>Tivic Health Systems, Inc. ((TIVC)) has held its Q3 earnings call. Read on for the main highlights of the call.</p>
<div class="lb-trans"><p>Tivic Health Systems, Inc. ((TIVC)) 已召開其第三季度財報電話會議。請繼續閲讀會議的主要亮點。</p>
</div><h3>Meet Your ETF AI Analyst</h3>
<div class="lb-trans"><h3>認識您的 ETF AI 分析師</h3>
</div><ul>
<li>Discover how TipRanks' <em>ETF</em> AI Analyst can help you make smarter investment decisions</li>
<li>Explore ETFs TipRanks' users love and see what insights the <strong><em>ETF</em> AI Analyst</strong> reveals about the ones you follow.</li>
</ul>
<div class="lb-trans"><ul>
<li>瞭解 TipRanks 的 <em>ETF</em> AI 分析師如何幫助您做出更明智的投資決策</li>
<li>探索 TipRanks 用户喜愛的 ETF，並查看 <strong><em>ETF</em> AI 分析師</strong> 對您關注的 ETF 的見解。</li>
</ul>
</div><p>Tivic Health Systems, Inc. has shown notable progress in its strategic transformation and development of Entolimod, despite facing challenges such as increased net loss and manufacturing delays. The overall sentiment during the earnings call was optimistic, highlighting the company’s advancements and improved financial position.</p>
<div class="lb-trans"><p>儘管面臨淨虧損增加和生產延遲等挑戰，Tivic Health Systems, Inc. 在其戰略轉型和 Entolimod 的開發方面取得了顯著進展。財報電話會議期間的整體情緒樂觀，突顯了公司的進步和改善的財務狀況。</p>
</div><h2>Strategic Transformation</h2>
<div class="lb-trans"><h2>戰略轉型</h2>
</div><p>Tivic Health has successfully expanded its focus from bioelectronics to biologic pharmaceuticals, particularly targeting treatments related to the immune system. This strategic shift marks a significant transformation for the company, positioning it in the promising field of biologic pharmaceuticals.</p>
<div class="lb-trans"><p>Tivic Health 成功地將其重點從生物電子學擴展到生物製藥，特別是針對與免疫系統相關的治療。這一戰略轉變標誌着公司的一次重大轉型，使其在生物製藥這一前景廣闊的領域中佔據了有利位置。</p>
</div><h2>Entolimod Development Progress</h2>
<div class="lb-trans"><h2>Entolimod 開發進展</h2>
</div><p>The company has made strides in the development of Entolimod by transferring two Investigational New Drug applications (INDs) and completing cell line verification. These steps are crucial as Tivic advances manufacturing readiness for Entolimod as a military countermeasure and stockpile drug.</p>
<div class="lb-trans"><p>公司在 Entolimod 的開發方面取得了進展，轉移了兩個新藥研究申請 (INDs) 並完成了細胞系驗證。這些步驟對於 Tivic 在將 Entolimod 作為軍事對策和儲備藥物的製造準備方面至關重要。</p>
</div><h2>Financial Position</h2>
<div class="lb-trans"><h2>財務狀況</h2>
</div><p>Tivic Health’s financial position has strengthened, with cash and cash equivalents rising to $3.5 million from $2 million, and the company maintaining a debt-free balance sheet. This improvement provides a solid foundation for future growth.</p>
<div class="lb-trans"><p>Tivic Health 的財務狀況得到加強，現金及現金等價物從 200 萬美元上升至 350 萬美元，公司保持無債務的資產負債表。這一改善為未來的增長提供了堅實的基礎。</p>
</div><h2>Gross Margin Improvement</h2>
<div class="lb-trans"><h2>毛利率改善</h2>
</div><p>The company reported an improvement in gross margins, excluding inventory reserves, which increased to 42% from 35% compared to the previous year. This indicates better cost management and efficiency in operations.</p>
<div class="lb-trans"><p>公司報告稱毛利率有所改善，排除庫存準備金後，毛利率從去年的 35% 增加至 42%。這表明成本管理和運營效率有所提升。</p>
</div><h2>Increased Net Loss</h2>
<div class="lb-trans"><h2>淨虧損增加</h2>
</div><p>Despite positive developments, Tivic Health experienced an increased net loss of $2.6 million for Q3 2025, compared to $1.4 million in Q3 2024. This rise in net loss reflects the company’s ongoing investments in its strategic transformation.</p>
<div class="lb-trans"><p>儘管有積極的發展，Tivic Health 在 2025 年第三季度的淨虧損增加至 260 萬美元，而 2024 年第三季度為 140 萬美元。這一淨虧損的增加反映了公司在其戰略轉型中的持續投資。</p>
</div><h2>Manufacturing Delays</h2>
<div class="lb-trans"><h2>生產延遲</h2>
</div><p>Tivic faced delays in its manufacturing schedule due to financial stress experienced by its contract manufacturer. These delays pose challenges to the company’s production timelines.</p>
<div class="lb-trans"><p>由於合同製造商面臨的財務壓力，Tivic 的生產計劃遭遇延遲。這些延遲對公司的生產時間表構成挑戰。</p>
</div><h2>Cost of Sales Increase</h2>
<div class="lb-trans"><h2>銷售成本增加</h2>
</div><p>The cost of sales rose significantly to $291,000 from $82,000, primarily due to inventory reserves. This increase impacts the company’s overall profitability.</p>
<div class="lb-trans"><p>銷售成本顯著上升至 291,000 美元，較 82,000 美元大幅增加，主要由於庫存準備金。這一增加影響了公司的整體盈利能力。</p>
</div><h2>Decreased Nine-Month Revenue</h2>
<div class="lb-trans"><h2>九個月收入下降</h2>
</div><p>Revenue for the nine-month period decreased to $302,000 from $600,000 in 2024, attributed to reduced unit sales. This decline highlights the challenges faced in maintaining sales momentum.</p>
<div class="lb-trans"><p>九個月期間的收入從 2024 年的 600,000 美元下降至 302,000 美元，歸因於單位銷售減少。這一下降突顯了在維持銷售勢頭方面面臨的挑戰。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指導</h2>
</div><p>Looking ahead, Tivic Health is committed to its strategic transformation towards the biopharmaceutical market, with a focus on Entolimod as a military countermeasure for acute radiation syndrome (ARS). The company has made progress in transferring INDs related to ARS and advanced cancer. Despite a decrease in nine-month revenue, Tivic is optimistic about its future, supported by improved gross margins and increased cash reserves.</p>
<div class="lb-trans"><p>展望未來，Tivic Health 致力於向生物製藥市場的戰略轉型，重點關注 Entolimod 作為急性輻射綜合症 (ARS) 的軍事對策。公司在與 ARS 和晚期癌症相關的 IND 轉移方面取得了進展。儘管九個月收入有所下降，Tivic 對未來持樂觀態度，得益於毛利率的改善和現金儲備的增加。</p>
</div><p>In conclusion, Tivic Health Systems, Inc. is navigating a transformative phase with a focus on biologic pharmaceuticals and the development of Entolimod. While the company faces challenges such as increased net loss and manufacturing delays, its improved financial position and strategic focus offer a promising outlook for the future.</p>
<div class="lb-trans"><p>總之，Tivic Health Systems, Inc. 正在經歷一個轉型階段，專注於生物製藥和 Entolimod 的開發。儘管公司面臨淨虧損增加和生產延遲等挑戰，但其改善的財務狀況和戰略重點為未來提供了良好的前景。</p>
</div>

Tivic Health 的財報電話會議：戰略調整與面臨的挑戰